- Home
- ZDGE vs PPCB Comparison
ZDGE vs PPCB Comparison
Compare ZDGE & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- PPCB
- Stock Information
- Founded
- ZDGE 2008
- PPCB 2007
- Country
- ZDGE United States
- PPCB Australia
- Employees
- ZDGE N/A
- PPCB N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- PPCB
- Sector
- ZDGE Technology
- PPCB
- Exchange
- ZDGE Nasdaq
- PPCB Nasdaq
- Market Cap
- ZDGE 39.9M
- PPCB 39.1M
- IPO Year
- ZDGE N/A
- PPCB N/A
- Fundamental
- Price
- ZDGE $3.17
- PPCB $1.91
- Analyst Decision
- ZDGE
- PPCB
- Analyst Count
- ZDGE 0
- PPCB 0
- Target Price
- ZDGE N/A
- PPCB N/A
- AVG Volume (30 Days)
- ZDGE 40.7K
- PPCB 316.9K
- Earning Date
- ZDGE 10-28-2025
- PPCB 09-30-2025
- Dividend Yield
- ZDGE N/A
- PPCB N/A
- EPS Growth
- ZDGE N/A
- PPCB N/A
- EPS
- ZDGE N/A
- PPCB N/A
- Revenue
- ZDGE $29,511,000.00
- PPCB N/A
- Revenue This Year
- ZDGE N/A
- PPCB N/A
- Revenue Next Year
- ZDGE $2.95
- PPCB N/A
- P/E Ratio
- ZDGE N/A
- PPCB N/A
- Revenue Growth
- ZDGE 1.27
- PPCB N/A
- 52 Week Low
- ZDGE $1.73
- PPCB $1.25
- 52 Week High
- ZDGE $4.89
- PPCB $145.46
- Technical
- Relative Strength Index (RSI)
- ZDGE 53.03
- PPCB N/A
- Support Level
- ZDGE $2.93
- PPCB N/A
- Resistance Level
- ZDGE $3.46
- PPCB N/A
- Average True Range (ATR)
- ZDGE 0.16
- PPCB 0.00
- MACD
- ZDGE 0.03
- PPCB 0.00
- Stochastic Oscillator
- ZDGE 48.39
- PPCB 0.00
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.